Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2009 Jan;50(1):12-17. Korean.
    Published online Jan 31, 2009.
    https://doi.org/10.4111/kju.2009.50.1.12
    Copyright © 2009 The Korean Urological Association
    Original Article

    Clinical Implications of the Expression of Survivin and p53 in Superficial Transitional Cell Carcinoma of the Bladder

    Dong Yun Kwak, Ji Yong Ha, Hyuk Soo Chang, Mi Sun Choi,1 Choal Hee Park, and Chun Il Kim
      • Department of Urology, Keimyung University School of Medicine, Daegu, Korea.
      • 1Department of Pathology, Keimyung University School of Medicine, Daegu, Korea.
    Received August 25, 2008; Accepted September 11, 2008.

    Abstract

    Purpose

    The prognostic value of p53 remains controversial in transitional cell carcinomas of the bladder. Survivin, an inhibitor of apoptosis, is expressed in many human cancers. Recent studies have reported increased expression of survivin in superficial transitional cell carcinomas of the bladder. We investigated the expression of survivin and p53 and the clinical implications of this expression in superficial transitional cell carcinomas of the bladder.

    Materials and Methods

    Immunohistochemical staining of paraffin sections using a monoclonal antibody for survivin and p53 was performed in 82 cases of superficial transitional cell carcinomas of the bladder. Correlations between the expression of survivin and p53 and clinicopathological features, such as age, multiplicity of tumor, size, recurrence, and progression, were examined.

    Results

    Among 82 cases, positive survivin expression (greater than 20%) was observed in 59 cases. Positive p53 expression (greater than 20%) was observed in 46 cases. There were no significant differences in age, gender, multiplicity, tumor size, tumor grade, pT stage, recurrence, or progression-free survival between p53-positive and p53-negative groups (p>0.05). Also, there were no significant differences in age, gender, multiplicity, tumor size, tumor grade, or pT stage between survivin-positive and survivin-negative groups (p>0.05). However, recurrent-free and progression-free survivals were significantly lower in the survivin-positive group than in the survivin-negative group (p<0.05).

    Conclusions

    The expression of survivin can be recommended as a useful marker for predicting disease recurrence and progression. Survivin may be superior to p53 as a prognostic factor in superficial transitional cell carcinoma of bladder.

    Keywords
    Urinary bladder neoplasms; Human BIRC5 protein; p53 genes

    Figures

    Fig. 1
    Immunohistochemical staining of survivin in tissue sections obtained from superficial bladder tumor. (A) Survivin was observed diffusely in bladder tumor tissue. Reduced from ×40 (brown staining). (B) Reduced from ×200 (brown staining).

    Fig. 2
    Immunohistochemical staining of p53 in tissue sections obtained from superficial bladder tumor. (A) p53 was observed diffusely in bladder tumor tissue. Reduced from ×40 (brown staining). (B) Reduced from ×200 (brown staining).

    Fig. 3
    Kaplan-Meier cumulative recurrence-free and progression-free curves of patients with superficial bladder tumor according to the survivin immunoreactivity. There were significant differences in recurrence-free (p=0.015) and progression-free survival (p=0.046) between the surviving-positive and survivin-negative groups.

    Fig. 4
    Kaplan-Meier cumulative recurrence-free and progression-free curves of patients with superficial bladder tumor according to p53 immunoreactivity. There were no significant differences in recurrence-free (p=0.081) and progression-free survival (p=0.793) between the p53-positive and p53-negative groups.

    Tables

    Table 1
    Clinicopathological characteristics according to survivin expression

    Table 2
    Clinicopathological characteristics according to p53 expression

    References

      1. Donat SM. Evaluation and follow-up strategies for superficial bladder cancer. Urol Clin North Am 2003;30:765–776.
      1. Lee ES, Lee CK, Lee C. Prognostic factors in superficial bladder tumor. Korean J Urol 1990;31:795–801.
      1. Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann MD, et al. Superficial bladder cancer: progression and recurrence. J Urol 1983;130:1083–1086.
      1. Fradet Y, Lacombe L. Can biological markers predict recurrence and progression of superficial bladder cancer? Curr Opin Urol 2000;10:441–445.
      1. Peyromaure M, Weibing S, Sebe P, Verpillat P, Toublanc M, Dauge MC, et al. Prognostic value of p53 overexpression in T1G3 bladder tumors treated with bacillus Calmette-Guerin therapy. Urology 2002;59:409–413.
      1. Dalbagni G, Parekh DJ, Ben-Porat L, Potenzoni M, Herr HW, Reuter VE. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 2007;99:281–285.
      1. Akhtar M, Gallagher L, Rohan S. Survivin: role in diagnosis, prognosis, and treatment of bladder cancer. Adv Anat Pathol 2006;13:122–126.
      1. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science 1995;267:1456–1462.
      1. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T, et al. IAP family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58:5315–5320.
      1. Ku JH, Kwak C, Lee HS, Park HK, Lee E, Lee SE. Expression of survivin, a novel inhibitor of apoptosis, in superficial transitional cell carcinoma of the bladder. J Urol 2004;171:631–635.
      1. Hockenbery D, Nunez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 1990;348:334–336.
      1. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev 1996;6:12–18.
      1. Crook NE, Clem RJ, Miller LK. An apoptosis-inhibiting baculovirus gene with a zinc finger-like motif. J Virol 1993;67:2168–2174.
      1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318–1327.
      1. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer angents. Cell 1993;74:957–967.
      1. Horowitz JM. Regulation of transcription by the retinoblastoma protein. Genes Chromosomes Cancer 1993;6:124–131.
      1. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 1994;152:388–392.
      1. Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, et al. Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guerin therapy: corrrelation to clinical outcomes. J Clin Oncol 1996;14:2646–2652.
      1. Gardiner RA, Walsh MD, Allen V, Rahman S, Samaratunga ML, Seymour GJ, et al. Immunohistological expression of p53 in primary pT1 transitional cell bladder cancer in relation to tumour progression. Br J Urol 1994;73:526–532.
      1. Shiina H, Igawa M, Nagami H, Yagi H, Urakami S, Yoneda T, et al. Immunohistochemical analysis of proliferating cell nuclear antigen, p53 protein and nm23 protein, and nuclear DNA content in transitional cell carcinoma of the bladder. Cancer 1996;78:1762–1774.
      1. Pages F, Flam TA, Vieillefond A, Molinie V, Abeille X, Lazar V, et al. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors. J Urol 1998;159:1079–1084.
      1. Pfister C, Moore L, Allard P, Larue H, Lacombe L, Tetu B, et al. Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence. Clin Cancer Res 1999;5:4079–4084.
      1. Swana HS, Grossman D, Anthony JN, Weiss RM, Altieri DC. Tumor content of the antiapoptosis molecule survivin and recurrence of bladder cancer. N Engl J Med 1999;341:452–453.
      1. Karam JA, Lotan Y, Ashfaq R, Sagalowsky AI, Shariat SF. Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder. Urology 2007;70:482–486.
      1. Nakanishi K, Tominaga S, Hiroi S, Kawai T, Aida S, Kasamatsu H, et al. Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract. Virchows Arch 2002;441:559–563.
    Cited by
    Crossref 2
    Google Scholar 
    Scopus 2
    MeSH Terms
    Apoptosis
    Carcinoma, Transitional Cell
    Disease-Free Survival
    Genes, p53
    Humans
    Paraffin
    Recurrence
    Urinary Bladder
    Urinary Bladder Neoplasms
    Metrics
    Share
    Figures
    slide
    slide
    slide
    slide

    1 / 4

    Tables
    slide
    slide

    1 / 2

    PERMALINK